nach oben

European Journal of Nutrition

Erschienen in:

14.03.2016 | Original Contribution

A meta-analysis of efficacy of Morus alba Linn. to improve blood glucose and lipid profile

verfasst von: Wiraphol Phimarn, Kittisak Wichaiyo, Khuntawan Silpsavikul, Bunleu Sungthong, Kritsanee Saramunee

Erschienen in: European Journal of Nutrition | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The previous studies have reported the Morus alba may improve blood glucose and lipid profile. The evidence from these studies is not consistent. This meta-analysis was to evaluate efficacy of products derived from M. alba on blood glucose and lipid levels.

Methods

Literature was reviewed via international database (PubMed, PubMed Central, ScienceDirect, and SciSearch) and Thai databases. Thirteen RCTs with high quality, assessed by Jadad score, were included.

Results

M. alba expressed a significant reduction in postprandial glucose (PPG) at 30 min (MD −1.04, 95 % CI −1.36, −0.73), 60 min (MD −0.87, 95 % CI −1.27, −0.48) and 90 min (MD −0.55, 95 % CI −0.87, −0.22). The difference was not found in the levels of other glycaemic (FBS, HbA1C, or HOMA-IR) and lipidaemic (TC, TG, LDL, or HDL) markers. Serious adverse effects were found neither in the control nor in the group received M. alba.

Conclusion

Products derived from M. alba can effectively contribute to the reduction in PPG levels, but large-scale RCTs would be informative.

Nur mit Berechtigung zugänglich

Falko M (2011) Balancing efficacy and tolerability issues with Statin Therapy—Considerations for the use of Pitavastatin in special patient populations. US Endocrinol 7:30–39. doi:10.17925/USE.2011.07.01.30 CrossRef

WHO (2015) Cardiovascular diseases (CVDs), Fact Sheet, 2009. http://www.who.int/mediacentre/factsheets/fs317/en/. Accessed August 15, 2015

Musunuru K (2010) Atherogenic dyslipidemia: cardiovascular risk and dietary intervention. Lipids 45:907–914CrossRef

Assmann G, Cullen P, Schulte H (2010) Non-LDL-related dyslipidemia and coronary risk: a case-control study. Diab Vasc Dis Res 7:204–212CrossRef

Davidson JA, Parkin CG (2009) Is hyperglycemia a causal factor in cardiovascular disease? Diab Care 32:s331–s333CrossRef

Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Borén J, Catapano AL, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Nordestgaard BG, Ray KK, Reiner Z, Taskinen MR, Tokgözoglu L, Tybjærg-Hansen A, Watts GF (2011) Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 32:1345–1361CrossRef

Tian L, Liu Y, Qin Y, Long S, Xu Y, Fu M (2010) Association of the low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio and concentrations of plasma lipids with high-density lipoprotein subclass distribution in the Chinese population. Lipids Health Dis 9:1–10. doi:10.1186/1476-511X-9-69 CrossRef

Wu T, Fu J, Yang Y, Zhang L, Han J (2009) The effects of phytosterols/stanols on blood lipid profiles: a systematic review with meta-analysis. Asia Pac J Clin Nutr 18:179–186

Derosa G, Sibilla S (2007) Optimizing combination treatment in the management of type 2 diabetes. Vasc Health Risk Manag 3:665–671

10.

Schuck RN, Mendys PM, Simpson RJ Jr (2013) Beyond statins: lipid management to reduce cardiovascular risk. Pharmacotherapy 33:754–764CrossRef

11.

Gangji AS, Cukierman T, Gerstein HC, Goldsmith CH, Clase CM (2007) A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diab Care 30:389–394CrossRef

12.

Salpeter SR, Greyber E, Pasternak GA, Salpeter EE (2003) Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Arch Int Med 163:2594–2602CrossRef

13.

Vermes A, Vermes I (2004) Genetic polymorphisms in cytochrome P450 enzymes: effect on efficacy and tolerability of HMG-CoA reductase inhibitors. Am J Cardiovasc Drugs 4:247–255CrossRef

14.

Golomb BA, Evans MA (2008) Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 8:373–418CrossRef

15.

Aramwit P, Supasyndh O, Siritienthong T, Bang N (2013) Mulberry leaf reduces oxidation and C-reactive protein level in patients with mild dyslipidemia. Biomed Res Int. doi:10.1155/2013/787981

16.

Asai A, Nakagawa K, Higuchi O, Kimura T, Kojima Y, Kariya J, Miyazawa T, Oikawa S (2011) Effect of mulberry leaf extract with enriched 1-deoxynojirimycin content on postprandial glycemic control in subjects with impaired glucose metabolism. J Diab Invest 2:318–323CrossRef

17.

Kim JY, Ok HM, Kim J, Park SW, Kwon SW, Kwon O (2015) Mulberry leaf extract improves postprandial glucose response in prediabetic subjects: a randomized, double-blind placebo-controlled trial. J Med Food 18:306–313CrossRef

18.

Choonwatchana N, Malaisit D (2015) Effect of mulberry leaf extract capsule on blood lipid profile of dyslipidemic patients. Dessertation. Mahasarakham University

19.

Trimarco V, Izzo R, Stabile E, Rozza F, Santoro M, Manzi MV, Serino F, Giacomo SG, Esposito G, Trimarco B (2015) Effects of a new combination of nutraceuticals with Morus alba on lipid profile, insulin sensitivity and endothelial function in dyslipidemic subjects. A cross-over, randomized, double-blind trial. High Blood Press Cardiovasc Prev 22:149–154CrossRef

20.

Chung HI, Kim J, Kim JY, Kwon O (2013) Acute intake of mulberry leaf aqueous extract affects postprandial glucose response after maltose loading: randomized double-blind placebo-controlled pilot study. J Funct Foods 13:1502–1506CrossRef

21.

Kim HJ, Yoon KH, Kang MJ, Yim HW, Lee KS, Vuksan V, Sung MK (2012) A six-month supplementation of mulberry, Korean red ginseng, and banana decreases biomarkers of systemic low-grade inflammation in subjects with impaired glucose tolerance and type 2 diabetes. Evid Based Complement Alternat Med. doi:10.1155/2012/735191

22.

Higgins J, Green SE (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration. http://http://handbook.cochrane.org/ Accessed 12 November, 2014

23.

Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. doi:10.1136/bmj.b2535

24.

Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12CrossRef

25.

Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA (2011) The cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. doi:10.1136/bmj.d5928

26.

The JAMA network (2000) SI conversion calculator. JAMA 283:134–135

27.

Egger M, Davey-Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634CrossRef

28.

Kimura T, Nakagawa K, Kubota H, Kojima Y, Goto Y, Yamagishi K, Oita S, Oikawa S, Miyazawa T (2007) Food-grade mulberry powder enriched with 1-deoxynojirimycin suppresses the elevation of postprandial blood glucose in humans. J Agric Food Chem 55:5867–5874CrossRef

29.

Mudra M, Ercan-Fang N, Zhong L, Furne J, Levitt M (2007) Influence of mulberry leaf extract on the blood glucose and breath hydrogen response to ingestion of 75 g sucrose by type 2 diabetic and control subjects. Diab Care 30:1272–1274CrossRef

30.

Nakamura S, Hashiguchi M, Yoshihiko Y, Oku T (2011) Hypoglycemic effects of Morus alba leaf extract on postprandial glucose and insulin levels in patients with type 2 diabetes treated with sulfonylurea hypoglycemic agents. J Diab Metab. doi:10.4172/2155-6156.1000158

31.

Sukriket P, Lookhanumanjao S, Bumrungpert A (2014) The effect of mulberry leaf tea on postprandial glycemic control and insulin sensitivity in pre-diabetic and non-diabetic subjects. http://www.mfu.ac.th/school/anti-aging/File_PDF/Research_PDF55/Proceeding_15.pdf. Accessed 15 Dec 2014

32.

Banu S, Jabir NR, Manjunath NC, Khan MS, Ashraf GM, Kamal MA, Tabrez S (2015) Reduction of post-prandial hyperglycemia by mulberry tea in type-2 diabetes patients. Saudi J Biol Sci 22:32–36CrossRef

33.

Banchobphutsa Y, Jarasphol R (2014) The efficacy of Morus alba leaf tea in patents with dyslipidemia. http://www.mfu.ac.th/school/anti-aging/File_PDF/Research_PDF55/Proceeding_7.pdf. Accessed 15 Dec, 2014

34.

Hu M, Zeng W, Tomlinson B (2014) Evaluation of a crataegus-based multiherb formula for dyslipidemia: a randomized, double-blind, placebo-controlled clinical trial. Evid Based Complement Alternat. doi:10.1155/2014/365742

35.

World Health Organisation (2000) General guidelines for methodologies on research and evaluation of traditional medicine. World Health Organisation, Geneva

36.

Hansawasdi C, Kawabata J (2006) Alpha-glucosidase inhibitory effect of mulberry (Morus alba) leaves on Caco-2. Fitoterapia 77:568–573CrossRef

37.

Habeeb MN, Naik PR, Moqbel FS (2012) Inhibition of α-glucosidase and α-amylase by Morus alba linn leaf extracts. J Pharm Res 5:285–289

38.

Vichasilp C, Nakagawa K, Sookwong P, Higuchi O, Kimura F, Miyazawa T (2012) A novel gelatin crosslinking method retards release of mulberry 1-deoxynojirimycin providing a prolonged hypoglycaemic effect. Food Chem 134:1823–1830CrossRef

39.

Asano N, Yamashita T, Yasuda K, Ikeda K, Kizu H, Kameda Y, Kato A, Nash RJ, Lee HS, Ryu KS (2011) Polyhydroxylated alkaloids isolated from mulberry trees (Morus alba L.) and silkworms (Bombyx mori L.). J Agric Food Chem 49:4208–4213CrossRef

40.

Nakagawa K (2013) Studies targeting α-glucosidase inhibition, antiangiogenic effects, and lipid modification regulation: background, evaluation, and challenges in the development of food ingredients for therapeutic purposes. Biosci Biotechnol Biochem 77:900–908CrossRef

41.

Lown M, Fuller R, Lightowler H, Fraser A, Gallagher A, Stuart B, Byrne CD, Lewith G (2015) Mulberry extract to modulate blood glucose responses in noRmoglYcaemic adults (MULBERRY): study protocol for a randomised controlled trial. Trials 16:486CrossRef

42.

Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M (2003) Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290:486–494CrossRef

43.

Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M (2004) Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 25:10–16CrossRef

44.

Chen JM, Chang CW, Lin YC, Horng JT, Sheu WH (2014) Acarbose treatment and the risk of cardiovascular disease in type 2 diabetic patients: a nationwide seven-year follow-up study. J Diab Res. doi:10.1155/2014/812628

45.

Yu PC, Bosnyak Z, Ceriello A (2010) The importance of glycated haemoglobin (HbA1c) and postprandial glucose (PPG) control on cardiovascular outcomes in patients with type 2 diabetes. Diab Res Clin Pract 89(1):1–9CrossRef

46.

Shishtar E, Sievenpiper JL, Djedovic V, Cozma AI, Ha V, Jayalath VH, Jenkins DJ, Meija SB, de Souza RJ, Jovanovski E, Vuksan V (2014) The effect of ginseng (The Genus Panax) on glycemic control: a systematic review and meta-analysis of randomized controlled clinical trials. PLoS ONE. doi:10.1371/journal.pone.0107391

47.

Kong WH, Oh SH, Ahn YR, Kim KW, Kim JH, Seo SW (2008) Antiobesity effects and improvement of insulin sensitivity by 1-deoxynojirimycin in animal models. J Agric Food Chem 56:2613–2619CrossRef

48.

Suo HS, Yan YH, Ko CH, Chen KM, Lee SC, Liu CT (2014) A comparison of food-grade folium mori (Sāng Yè) extract and 1-deoxynojirimycin for glycemic control and renal function in streptozotocin-induced diabetic rats. J Tradit Complement Med 4:162–170CrossRef

49.

Kojima Y, Kimura T, Nakagawa K, Asai A, Hasumi K, Oikawa S, Miyazawa T (2010) Effects of mulberry leaf extract rich in 1-deoxynojirimycin on blood lipid profiles in human. J Clin Biochem Nutr 47:155–161CrossRef

Titel: A meta-analysis of efficacy of Morus alba Linn. to improve blood glucose and lipid profile
verfasst von: Wiraphol Phimarn
Kittisak Wichaiyo
Khuntawan Silpsavikul
Bunleu Sungthong
Kritsanee Saramunee
Publikationsdatum: 14.03.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nutrition / Ausgabe 4/2017
Print ISSN: 1436-6207
Elektronische ISSN: 1436-6215
DOI: https://doi.org/10.1007/s00394-016-1197-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2017

Consumption of polyphenol-rich Morus alba leaves extract attenuates early diabetic retinopathy: the underlying mechanism

Comments on “Soy isoflavone intake and its association with depressive symptoms during pregnancy”: consider sleep and physical activity as possible confounders

Choline and polyunsaturated fatty acids in preterm infants’ maternal milk

Increased plasma levels of glucose-dependent insulinotropic polypeptide are associated with decreased postprandial energy expenditure after modern Japanese meals

Soy isoflavone intake and depressive symptoms during pregnancy

Dietary fat may modulate adipose tissue homeostasis through the processes of autophagy and apoptosis